Phase 4 Acupuncture vs Medication for Anxiety and Depression in China
Summary
A new Phase 4 clinical trial (NCT07552246) has been registered comparing acupuncture against standard SSRI medication for treating anxiety and mild-to-moderate depression in adults in China. The study aims to identify the most cost-effective and environmentally sustainable intervention between the two approaches. Conditions studied include Anxiety and Depression, with interventions including Selective Serotonin Reuptake Inhibitor (SSRI) and Acupuncture as standalone comparators.
“The main objective of this study is to compare medication (usual care) with acupuncture (as a standalone comparator) to identify the most (cost)effective and environmentally sustainable intervention to reduce anxiety and mild to moderate depression in adults in China.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 4 clinical trial (NCT07552246) has been registered on ClinicalTrials.gov. The trial will compare acupuncture (as a standalone intervention) against standard SSRI medication (usual care) to reduce anxiety and mild to moderate depression in adults in China. The study's objective includes identifying the most cost-effective and environmentally sustainable intervention.
For researchers and healthcare providers, this trial represents an additional data point in the comparative effectiveness literature for mental health treatments. The focus on both clinical outcomes and cost/environmental sustainability may appeal to healthcare systems seeking value-based and ecologically mindful treatment options. No compliance obligations are created by this registration.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Comparing Acupuncture With Medication to Reduce Anxiety and Depression in China
Phase 4 NCT07552246 Kind: PHASE4 Apr 27, 2026
Abstract
The main objective of this study is to compare medication (usual care) with acupuncture (as a standalone comparator) to identify the most (cost)effective and environmentally sustainable intervention to reduce anxiety and mild to moderate depression in adults in China.
Conditions: Anxiety Depression
Interventions: Selective serotonin reuptake inhibitor (SSRI), Acupuncture
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.